Imaging of Bacteria: Is there Any Hope for the Future Based on Past Experience?

Author(s): Thomas Ebenhan, Elena Lazzeri, Olivier Gheysens*.

Journal Name: Current Pharmaceutical Design

Volume 24 , Issue 7 , 2018


Infectious diseases remain a major health problem and cause of death worldwide. It is expected that the socio-economic impact will further intensify due to escalating resistance to antibiotics, an ageing population and an increase in the number of patients under immunosuppressive therapy and implanted medical devices. Even though radiolabeled probes and leukocytes are routinely used in clinical practice, it might still be difficult to distinguish sterile inflammation from inflammation caused by bacteria. Moreover, the majority of these probes are based on the attraction of leukocytes which may be hampered in neutropenic patients. Novel approaches that can be implemented in clinical practice and allow for swift diagnosis of infection by targeting the microorganism directly, are posing an attractive strategy. Here we review the current strategies to directly image bacteria using radionuclides and we provide an overview of the preclinical efforts to develop and validate new approaches. Indeed, significant progress has been made in the past years, but very few radiopharmaceuticals (that were promising in preclinical studies) have made it into clinical practice. We will discuss the challenges that remain to select good candidates for imaging agents targeting bacteria.

Keywords: Radionuclide imaging, bacterial infection, antimicrobial peptides, radiolabeled leukocytes, biomimetics, antibiotics.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Page: [772 - 786]
Pages: 15
DOI: 10.2174/1381612823666171122111558
Price: $58

Article Metrics

PDF: 20